Lexipafant is a platelet-activating factor (PAF) antagonist. It was hypothesized that the substance could beneficially affect the cognitive performance of HIV infected people. Lexipafant was as tolerable as placebo. At week 6 and week 10 after baseline evaluations, the lexipafant group showed trends toward improvement on the Rey Auditory Verbal Learning test as well as the timed gait test. A phase IIa placebo-controlled study reported that lexipafant was not effective in patients with severe ulcerative colitis receiving corticosteroids. Two lexipafant treated patient had adverse events: severe influenza-like symptoms in one and hypotension with iliac artery thrombosis in one. The clinical trials of lexipafant in the treatment of acute pancreatitis were undertaken with considerable optimism. There was a significant reduction in the incidence of organ failure and in total organ failure score at the end of medication (72 h).